Search research articles
Contact Us
Filters
Showing results (181-190 of 312) with videos related to
Page
of 32
Sort By:
Future Oncology (London, England)
|
February 9, 2018
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET
Scott C Flanders, Janet Kim, Samuel Wilson, et al.
European Urology Focus
|
December 19, 2025
Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and Challenges
Neal D Shore, Stephen J Freedland, Lisa G Horvath, et al.
Future Oncology (London, England)
|
June 2, 2025
rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC
Kim Nguyen Chi, Rana R McKay, Shahneen Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2019
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J Armstrong, Russell Z Szmulewitz, Daniel P Petrylak, et al.
The New England Journal of Medicine
|
May 30, 2020
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal D Shore, Fred Saad, Michael S Cookson, et al.
Urology
|
January 14, 2014
Challenges and recommendations for early identification of metastatic disease in prostate cancer
E David Crawford, Nelson N Stone, Evan Y Yu, et al.
The Prostate
|
August 12, 2020
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians
Neal D Shore, Charles G Drake, Daniel W Lin, et al.
European Urology Open Science
|
June 22, 2026
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer
Jennifer Linehan, Piyush K Agarwal, Xianne Penny, et al.
Future Oncology (London, England)
|
December 12, 2024
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Future Oncology (London, England)
|
June 30, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review
Paul E Dato, Jose De La Cerda, Andrew J Armstrong, et al.
Page
of 32
Search research articles
Search
Showing results (181-190 of 312) with videos related to
Sort By:
Page
of 32
Future Oncology (London, England)
|
February 9, 2018
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET
Scott C Flanders, Janet Kim, Samuel Wilson, et al.
European Urology Focus
|
December 19, 2025
Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and Challenges
Neal D Shore, Stephen J Freedland, Lisa G Horvath, et al.
Future Oncology (London, England)
|
June 2, 2025
rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC
Kim Nguyen Chi, Rana R McKay, Shahneen Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2019
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J Armstrong, Russell Z Szmulewitz, Daniel P Petrylak, et al.
The New England Journal of Medicine
|
May 30, 2020
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal D Shore, Fred Saad, Michael S Cookson, et al.
Urology
|
January 14, 2014
Challenges and recommendations for early identification of metastatic disease in prostate cancer
E David Crawford, Nelson N Stone, Evan Y Yu, et al.
The Prostate
|
August 12, 2020
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians
Neal D Shore, Charles G Drake, Daniel W Lin, et al.
European Urology Open Science
|
June 22, 2026
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer
Jennifer Linehan, Piyush K Agarwal, Xianne Penny, et al.
Future Oncology (London, England)
|
December 12, 2024
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Future Oncology (London, England)
|
June 30, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review
Paul E Dato, Jose De La Cerda, Andrew J Armstrong, et al.
Page
of 32